SRR1456294
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.414
- KRAS_SIGNALING_DN+0.406
- COAGULATION+0.282
- SPERMATOGENESIS+0.199
- INFLAMMATORY_RESPONSE+0.198
- ANGIOGENESIS+0.197
- ALLOGRAFT_REJECTION+0.170
- COMPLEMENT+0.161
- ESTROGEN_RESPONSE_LATE+0.161
- XENOBIOTIC_METABOLISM+0.160
Top 10 suppressed
- MYC_TARGETS_V1-0.562
- PROTEIN_SECRETION-0.489
- DNA_REPAIR-0.463
- G2M_CHECKPOINT-0.452
- UNFOLDED_PROTEIN_RESPONSE-0.432
- MYC_TARGETS_V2-0.428
- E2F_TARGETS-0.421
- MITOTIC_SPINDLE-0.410
- NOTCH_SIGNALING-0.397
- OXIDATIVE_PHOSPHORYLATION-0.376
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR662091 | GTEX | — | 0.953 |
| 2 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.952 |
| 3 | SRR1416754 | GTEX | — | 0.937 |
| 4 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.934 |
| 5 | BS_0X9EGHY2 | low-grade glioma | — | 0.927 |
| 6 | SRR1382956 | GTEX | — | 0.924 |
| 7 | SRR1336887 | GTEX | — | 0.922 |
| 8 | BS_PQ7CQFYR | Ganglioglioma | — | 0.921 |
| 9 | SRR1387032 | GTEX | — | 0.919 |
| 10 | SRR1459423 | GTEX | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.414 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.406 | Remibrutinib | — uncovered |
| COAGULATION | 0.282 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.199 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.198 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.197 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| COMPLEMENT | 0.161 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.161 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.152 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.108 | Inavolisib | — uncovered |
| MYOGENESIS | 0.069 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.028 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.026 | Inavolisib | — uncovered |